期刊文献+

代谢综合征合并心血管疾病的二级综合干预研究

The research on the metabolic syndrome merger with cardiovascular disease treatment intervention
原文传递
导出
摘要 目的:探讨对代谢综合征(MS)合并心血管疾病(CVD)患者实施综合干预治疗措施的效果。方法:对103例MS合并CVD患者推荐及指导综合干预治疗方案,进行相关检查,记录心血管事件发生情况,最后按是否依从干预治疗方案及是否达到标准效果分为3组(正规治疗组、非正规治疗组及未治疗组),比较3组患者的血脂、BP、FBS、颈动脉粥样斑块数与基础值的变化情况以及心血管事件、脑血管事件和死亡(排除癌症、意外死亡等)的发生情况。结果:(1)3组患者入选时观察指标基础值无统计学差异;(2)正规治疗组心血管事件发生次数及颈动脉粥样斑块数明显减少(P<0.05);(3)控制危险因素的时间越早、治疗时间越长,则控制效果越好、出现的心血管事件也越少,而且控制血压比控制血糖更为重要。结论:综合干预治疗方案是MS合并CVD患者的有效防治方案,而指导患者坚持治疗并使防治效果达标是为关键。 Objective:The purpose of analyzing the metabolic syndrome merger with cardiovascular disease treatment intervention is to explore a comprehensive treatment intervention model to achieve the effect of prevention and treatment in order to provide some evidences for intervention. Methods : Carry on the related inspection to 103 cases conforming to metabolism syndrome merge cardiovascular disease, take the record of treatment result and the occurrence of cardiovascular events, and finally press the treatment result the situation to carry on the grouping. Results: Three groups of ordinary circumstances do not have the difference, the group with regular treats has the obvious reduction to have the cardiovascular event and the gruel type hardening(P〈0. 05). The longer treatment control time is, the lower cardiovascular event formation rate will be(P〈0. 05). Controls of the blood pressure, the blood sugar, the blood fats to metabolism syndrome many hazard factors in were the foundation. Moreover it was more important to control the blood pressure than the blood sugar. Conclusions:MS was an integrated intervention in the treatment of the merger of major CVD prevention and treatment programs, whether or not the secondary effect was the key target.
机构地区 广东韶钢医院
出处 《中国冶金工业医学杂志》 2009年第3期269-270,共2页 Chinese Medical Journal of Metallurgical industry
关键词 代谢综合征 心血管疾病 综合干预 Metabolic syndrome Cardiovascular disease Treatment intervention
  • 相关文献

参考文献6

  • 1Isommaa B, Almgren P, TuomiT, et al. Cardiovascular movbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001,24 : 683-689.
  • 2中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3053
  • 3Caglayan E, Blaschke F, TaKata Y, etal. Metabolic syndromeinterdependence of the cardiovascular and metabolic pathways. Curr Opin Pharmacol, 2005,5 : 135-142.
  • 4Isomaa B. Amajor health hazard:the metabolic Syndrome. Life Sci, 2003,73 : 2395-2411.
  • 5徐成斌.代谢综合征(4)[J].中国医刊,2005,40(5):2-5. 被引量:38
  • 6Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women ; a report from the Women's lschemia Syndrome Evaluation (WISE) study[J]. Circulation,2004,109:706-713.

二级参考文献3

共引文献3076

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部